Stéphane Champiat

15PUBLICATIONS
240CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)AllergyGene and molecular therapyLiquid biopsies
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Sep 23, 2026
Gustave Roussy Immune Score Validation in Patients Treated with Bispecific CD3 T-cell Engagers in Phase I Clinical Trials.

|Aug 27, 2025
Modulating Treatment Outcomes of Patients with Solid Tumors in Immunotherapy Trials: A Drug Interaction Analysis from a Phase I Unit.

Camila Braganca Xavier, Clark R Andersen, JoAnn Lim

|Jun 11, 2025
Phase I and II Clinical Studies of the STING Agonist Ulevostinag with and without Pembrolizumab in Participants with Advanced or Metastatic Solid Tumors or Lymphomas.

Kevin J Harrington, Stephane Champiat, Joshua D Brody

|Mar 28, 2025
A Phase I, First-in-Human, Dose-Escalation, Expansion Trial of Cytokine-Encoding Synthetic mRNA Mixture Alone or with Cemiplimab in Advanced Solid Tumors.

Oliver Bechter, Carmen Loquai, Stephane Champiat

|Aug 29, 2024
Sustained Clinical Benefit and Intracranial Activity of Tarlatamab in Previously Treated Small Cell Lung Cancer: DeLLphi-300 Trial Update.

Afshin Dowlati, Horst-Dieter Hummel, Stephane Champiat

|May 30, 2024
Impact of Clonal Hematopoiesis-Associated Mutations in Phase I Patients Treated for Solid Tumors: An Analysis of the STING Trial.

Julieta Rodriguez, Capucine Baldini, Arnaud Bayle

Pageof 3

Frequent Collaborators

8 joint publications

Aurélien Marabelle

3 joint publications

Lambros Tselikas

3 joint publications

Christophe Massard

3 joint publications

Samy Ammari